ENOB | Enochian Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.7000 - 0.7450
52 Week Range	0.3930 - 2.9900
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	87,289
Average Volume	254,603
Shares Outstanding	63,698,100
Market Cap	45,384,896
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-02-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.34
Forward P/E Ratio	N/A
EPS	-2.07
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	22
Country	USA
Website	ENOB

Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in identifying, developing, manufacturing, and commercializing gene therapies. The company develops cures and providing prevention for infectious diseases and cancer. It is also engaged in developing HIV preventative vaccines and cures and Cellular immune-oncology products.

ENOB's peers: ACXP, CADL, CDXC, CLGN, ENTX, LIXT, MNPR, QLGN, RLMD, XCUR, QNCX, THRD, PROK, CVKD

*Chart delayed

Analyzing fundamentals for ENOB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ENOB Fundamentals page.

Watching at ENOB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ENOB Technicals page.